GEHC— AI Stock Forecast & Price Targets
Published 7/1/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live GEHC price forecast →
GE HealthCare (GEHC) shows resilience with strong fundamentals and strategic AI-driven product launches, but faces near-term valuation pressure from a 23% YTD drawdown. Kronos forecasts indicate a recovery toward the high-$70s over the next 6-12 months, supported by robust margins and cash flow, though earnings volatility remains a concern.
Hold until earnings on July 29; invalidation below $64.01. Target $72.27 as pre-earnings catalyst, but avoid swing trades due to IV crush risk.
Accumulate if price dips below $65.05 (current close), targeting $78.71 with 12mo horizon. Catalysts include AI-driven product adoption and market expansion in neonatal care (7.9% CAGR).
Terminal thesis: GEHC could reach $80+ by leveraging cloud imaging tools and Allia upgrade pathways, but secular risks like regulatory shifts or competition from startups may cap upside.
Revenue grew 5.97% Y/Y TTM with stable gross margins at 38.84%, though operating margins compressed to 13.38% from 14.5% in Q4'25. Strong cash flow ($1.48B FCF) and low debt-to-equity (0.99x) support quality, but the 23% YTD drawdown and $65.76 price at time of news indicate valuation pressure. The dividend yield of 0.22% is modest, yet consistent with healthcare sector norms.
The chart shows a bullish trend with green actual price above yellow Kronos forecast band (actual: $65.18 vs forecast: $72.27). Support at $64.01 and resistance near $72.27 align with the forecast band, while RSI of 49.93 suggests neutral momentum. The model's directional accuracy is 60% for 1d/60% naive baseline, indicating moderate reliability in short-term moves.
Key news includes a $0.035 quarterly dividend and Allia upgrade pathways for interventional suites, signaling product modernization. The neonatal care market report (7.9% CAGR to $8.94B by 2035) highlights growth potential. However, the recent 23% YTD drawdown and Q1 margin compression (operating margin fell to 10.0%) indicate near-term volatility.
- Allia upgrade pathways for legacy systems to modernize interventional suites (announced June 29) with AI workflows
- Neonatal care market growth at 7.9% CAGR to $8.94B by 2035
- Q1 margin compression to 10.0% from 14.5% in Q4'25 indicates operational challenges
- Valuation pressure with forward P/E of 12.15x vs sector average of 15.6x
- Earnings volatility with EPS Y/Y TTM at -12.36%
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord